Loading…
Swiss maker of injection pens, insulin pumps and auto-injector devices delivering diabetes and other injectable drugs.
Swiss maker of injection pens, insulin pumps and auto-injector devices delivering diabetes and other injectable drugs.
Mostly designs and makes injection devices that drug companies build into their own products, paid through long-term supply agreements, so volumes continue for as long as the partner's drug sells. Its own diabetes pumps and pens are sold through pharmacies and insurers. Founder Willy Michel remains the controlling shareholder.
In one line: A device-only peer to Insulet, supplying pens/pumps rather than the drug.
Moat: narrow (switching costs, IP, customer qualification). Long device-qualification cycles with pharma partners and patient habituation create stickiness.
Headquarters: Burgdorf, Switzerland · Founded: 1984 · Employees: 2,025
Size Ypsomed (YPSN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $6.35B, the 48th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 394.40 on 6 Nov 2026.
Performance Over six months the shares gained 30.2%, against +25.2% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 2.4% over the last twelve months (peer median +6.3%); the operating margin is 25.3% (peer median 13.9%).
Valuation It trades at 30.1× forward earnings against a peer median of 20.6× (3rd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.6 points above its cost of capital (5.6% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 731M | CHF 731M | CHF 749M | CHF 548M | CHF 497M |
| Revenue growth | — | -2% | +37% | +10% | — |
| Gross profit | CHF 315M | CHF 315M | CHF 292M | CHF 220M | CHF 141M |
| EBITDA | CHF 267M | CHF 267M | CHF 213M | CHF 156M | CHF 116M |
| Net income | CHF 222M | CHF 222M | CHF 87.5M | CHF 78.4M | CHF 51.3M |
| Free cash flow | CHF 11.2M | CHF 11.2M | -CHF 57.4M | CHF 46.8M | CHF 30.7M |
| Capital expenditure | CHF 323M | CHF 323M | CHF 277M | CHF 195M | CHF 169M |
| Total debt | n/a | CHF 261M | CHF 367M | CHF 256M | CHF 157M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ypsomed YPSN.SW | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% |
| Insulet PODD | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% |
| Tandem Diabetes Care TNDM | $1.18B | +9% | +4% | -4% | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | YPSN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.0% | +9.1% | 9th highest of 21 |
| 6-month return | +30.2% | +25.2% | 10th highest of 21 |
| Distance from 52-week high | -5.7% | -9.8% | 7th highest of 21 |
| Revenue growth (TTM) | -2.4% | +6.3% | 4th lowest of 21 |
| Operating margin | 25.3% | 13.9% | 5th highest of 21 |
| Forward P/E | 30.1× | 20.6× | 3rd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 11.5% | 10.9% | 8th most demanding of 19 |
| Growth delivered (Del g) | +12.6% | +9.1% | 5th highest of 19 |
| Hurdle (Req g minus delivered) | -1.1 pp | +1.6 pp | 7th least demanding of 19 |
| ROIC minus cost of capital | +9.6 pp | +3.1 pp | 5th highest of 21 |
| EV / EBITDA | 20.3× | 14.2× | 3rd most expensive of 17 |
| Net debt / EBITDA | 0.9× | 1.0× | 8th least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |